Phospho-TNNI3 (T142) Antibody

What is TNNI3 and why is phosphorylation at T142 significant?

TNNI3 (Troponin I type 3) is the cardiac-specific isoform of troponin I, functioning as the inhibitory component of the troponin complex that regulates calcium-dependent muscle contraction in the heart. The phosphorylation at threonine 142 (T142) is particularly significant as it represents a protein kinase C (PKC) phosphorylation site unique to cardiac troponin I. This phosphorylation site is located within the inhibitory region of the protein that directly interacts with cardiac troponin C (cTnC) .

Research using NMR spectroscopy has demonstrated that T142 phosphorylation dramatically reduces (by approximately 14-fold) the binding affinity of the inhibitory region of cardiac troponin I (cIp) for the C-domain of cardiac troponin C (cCTnC·2Ca²⁺) . This modification affects the calcium-dependent regulation of cardiac muscle contraction by impairing the transmission of calcium signals to other myofilament proteins . The normal switching mechanism between contraction and relaxation involves movement of the inhibitory region of cTnI between cTnC and actin-tropomyosin, and phosphorylation at T142 significantly disrupts this crucial interaction .

How does the sequence context of T142 contribute to its functional role?

The T142 residue in TNNI3 is positioned within the highly conserved inhibitory region (approximately residues 128-147) that plays a critical role in the regulation of muscle contraction. Based on the mouse TNNI3 sequence (UniProt P48787), T142 is located in a region that directly interacts with the C-domain of cardiac troponin C .

The inhibitory region contains multiple functionally important residues, including the R145 position (sometimes numbered as R144G in different referencing systems), which is associated with familial hypertrophic cardiomyopathy when mutated . The proximity of T142 to this disease-associated mutation site highlights the critical regulatory function of this region in cardiac physiology.

The full sequence context surrounding T142 contributes to its ability to be recognized by protein kinase C, and phosphorylation introduces a negative charge that disrupts the electrostatic interactions important for binding to troponin C . This molecular mechanism provides the basis for how PKC-mediated phosphorylation at this site affects cardiac muscle function under both normal and pathological conditions.

What criteria should guide the selection of a phospho-TNNI3 (T142) antibody?

When selecting a phospho-TNNI3 (T142) antibody for research applications, researchers should consider several critical factors:

• Phospho-specificity: The antibody must specifically recognize TNNI3 that is phosphorylated at T142 while showing minimal cross-reactivity with unphosphorylated TNNI3 or TNNI3 phosphorylated at other sites. Products like ab58546 have been validated for phospho-specificity through peptide competition assays .

• Species reactivity: Verify that the antibody recognizes the appropriate species for your research. For example, AF7807 reacts with human, mouse, and rat TNNI3 , while ab58546 shows reactivity with mouse, rat, pig, and human samples .

• Application compatibility: Ensure the antibody is validated for your intended experimental methods. AF7807 is suitable for Western blot (WB) and immunofluorescence/immunocytochemistry (IF/ICC) , while ab58546 is validated for ELISA and WB applications .

• Validation data: Review the available validation data, including Western blot images showing the expected molecular weight (note that TNNI3 often migrates at ~30 kDa despite a predicted size of 24 kDa) .

• Antibody type and host: Consider whether a monoclonal or polyclonal antibody is more appropriate for your application. Polyclonal antibodies like ab58546 may offer higher sensitivity but potentially less specificity than monoclonal antibodies .

• Immunogen information: Review the peptide sequence used to generate the antibody to understand the epitope context. For example, ab58546 was generated using a synthetic peptide within Human TNNI3 phospho T143 (equivalent to T142 in some numbering systems) amino acids 100-200 .

What controls are essential for validating phospho-TNNI3 (T142) antibody specificity?

To ensure reliable results when working with phospho-TNNI3 (T142) antibodies, implement these essential controls:

• Peptide competition assay: Pre-incubate the antibody with the phosphorylated immunizing peptide before application to your samples. A specific phospho-antibody will show significantly reduced or absent signal when the competing phosphopeptide is present, as demonstrated for ab58546 .

• Phosphatase treatment control: Treat a duplicate sample with lambda phosphatase to remove phosphate groups. The phospho-specific antibody should show diminished signal in phosphatase-treated samples compared to untreated samples.

• Kinase activation/inhibition: Include samples from cardiac tissues or cells treated with PKC activators (e.g., phorbol esters) to increase T142 phosphorylation and PKC inhibitors to decrease phosphorylation. These treatments should produce corresponding changes in signal intensity.

• Total TNNI3 detection: Always run parallel blots with a non-phospho-specific TNNI3 antibody to normalize for total protein levels and to confirm that changes in phospho-signal reflect actual phosphorylation changes rather than alterations in protein expression.

• Genetic controls: When available, use cardiac tissue or cells from TNNI3 T142A mutants (where threonine is replaced with non-phosphorylatable alanine) as a negative control.

What is the optimal protocol for detecting phospho-TNNI3 (T142) in cardiac samples?

For reliable detection of phospho-TNNI3 (T142) in cardiac samples, the following optimized protocol is recommended:

Sample Preparation:

• Harvest cardiac tissue and immediately freeze in liquid nitrogen to preserve phosphorylation status.

• Homogenize tissue in ice-cold lysis buffer containing comprehensive phosphatase inhibitors (e.g., 50 mM NaF, 1 mM Na₃VO₄, 10 mM β-glycerophosphate, and commercial phosphatase inhibitor cocktail).

• Maintain samples at 4°C throughout processing to minimize dephosphorylation.

• Clarify lysates by centrifugation (14,000 × g, 10 minutes, 4°C).

• Determine protein concentration using a detergent-compatible assay.

Western Blot Procedure:

• Separate 25-50 μg of protein on a 12-15% SDS-PAGE gel (expected molecular weight of TNNI3 is ~24 kDa, though it often migrates at ~30 kDa) .

• Transfer proteins to PVDF membrane (recommended over nitrocellulose for phosphoproteins).

• Block with 5% BSA in TBST (not milk, which contains phosphoproteins that may interfere).

• Incubate with phospho-TNNI3 (T142) antibody at manufacturer's recommended dilution (e.g., 1:500 for ab58546) in 5% BSA/TBST overnight at 4°C .

• Wash extensively with TBST (4 × 10 minutes).

• Incubate with appropriate HRP-conjugated secondary antibody.

• Develop using enhanced chemiluminescence and image.

Immunofluorescence Protocol:

• Fix cardiac tissue sections or isolated cardiomyocytes with 4% paraformaldehyde.

• Permeabilize with 0.2% Triton X-100.

• Block with 10% normal serum from secondary antibody host species.

• Incubate with phospho-TNNI3 (T142) antibody at recommended dilution overnight at 4°C.

• Wash thoroughly with PBS.

• Incubate with fluorophore-conjugated secondary antibody.

• Counterstain nuclei with DAPI and mount with anti-fade medium.

How can researchers effectively quantify changes in TNNI3 T142 phosphorylation?

To accurately quantify changes in TNNI3 T142 phosphorylation:

• Normalization approach: Always normalize phospho-TNNI3 (T142) signal to total TNNI3 to account for variations in protein loading and expression. This requires running parallel blots or stripping and reprobing with total TNNI3 antibody.

• Densitometric analysis: Use digital imaging systems and analysis software to quantify band intensities. Ensure images are captured within the linear range of detection to avoid saturation.

• Multiple biological replicates: Analyze at least three independent biological samples per experimental condition to account for biological variability.

• Statistical analysis: Apply appropriate statistical tests based on experimental design. For comparing multiple conditions, use ANOVA with post-hoc tests; for two conditions, use t-tests or non-parametric alternatives if normality assumptions are not met.

• Time-course experiments: For dynamic phosphorylation studies, collect samples at multiple time points following stimulation (e.g., 0, 5, 15, 30, 60 minutes after PKC activation).

• Dose-response relationships: When using pharmacological agents, establish dose-response curves to determine optimal concentrations for modulating T142 phosphorylation.

• Internal controls: Include positive controls (PKC-activated samples) and negative controls (PKC-inhibited samples) in each experiment to validate assay performance.

How does T142 phosphorylation alter the interaction between TNNI3 and troponin C?

T142 phosphorylation has profound effects on the molecular interactions that govern cardiac muscle contraction:

• Binding affinity reduction: NMR spectroscopy studies have demonstrated that T142 phosphorylation reduces the binding affinity of the inhibitory region of cardiac troponin I (cIp) for the C-domain of cardiac troponin C (cCTnC·2Ca²⁺) by approximately 14-fold . This substantial reduction in affinity directly impacts the calcium-dependent regulation of muscle contraction.

• Binding epitope preservation: Despite the dramatic reduction in binding affinity, NMR chemical shift mapping indicates that the binding epitope of cIp on cCTnC·2Ca²⁺ is not significantly altered by phosphorylation . This suggests that phosphorylation affects the strength rather than the mode of binding.

• Molecular mechanism: The phosphorylation of T142 introduces a negative charge that likely disrupts favorable electrostatic interactions between the inhibitory region of troponin I and the C-domain of troponin C . This disruption weakens the interaction without completely abolishing it.

• Functional consequences: The weakened interaction between troponin I and troponin C affects the transmission of calcium signals to other myofilament proteins and disrupts the normal switching mechanism between contraction and relaxation states . This molecular alteration provides a mechanism for how PKC-mediated phosphorylation contributes to altered cardiac function.

What is the interplay between T142 phosphorylation and cardiomyopathy-associated mutations?

Research has revealed important interactions between T142 phosphorylation and cardiac disease-associated mutations in TNNI3:

• Synergistic effects with R145G mutation: The R145G mutation (sometimes referenced as R144G) is associated with familial hypertrophic cardiomyopathy and is located near the T142 phosphorylation site in the inhibitory region of TNNI3 . Studies show that:

  • T142 phosphorylation alone reduces binding affinity to cCTnC·2Ca²⁺ by ~14-fold

  • R145G mutation alone reduces binding affinity by ~4-fold

  • Combined T142 phosphorylation and R145G mutation reduces binding affinity by ~19-fold

  This indicates a slightly synergistic effect where the disease-associated mutation enhances the functional impact of phosphorylation.

• Molecular basis for disease mechanism: The combined effect of phosphorylation and mutation provides insight into how genetic variants may exacerbate cardiac dysfunction under conditions of increased PKC activity, such as during heart failure or ischemia . This interplay could help explain the variable disease presentation in patients with the same genetic mutation.

• Structural implications: Both T142 phosphorylation and the R145G mutation affect a critical region of troponin I that undergoes significant movement during the transition between contraction and relaxation states . The combined effect likely severely compromises this mechanical function.

• Potential therapeutic implications: Understanding this interplay suggests that PKC inhibitors might be particularly beneficial for patients with specific TNNI3 mutations that sensitize the protein to the effects of phosphorylation.

How does T142 phosphorylation compare with other TNNI3 phosphorylation sites?

TNNI3 contains multiple phosphorylation sites that collectively regulate cardiac function. Comparing T142 phosphorylation with other sites reveals important distinctions:

• Regional phosphorylation patterns: TNNI3 contains phosphorylation sites in distinct functional regions, including the N-terminal cardiac-specific region (S23/24), the inhibitory region (T142), and the switch region (S149) . The location of these sites in different functional domains explains their diverse effects on cardiac function.

• Kinase-specific regulation: Different kinases target specific sites in TNNI3:

  • PKA primarily phosphorylates S23/24

  • PKC phosphorylates multiple sites including T142

  • PAK (p21-activated kinase) phosphorylates S149

  This kinase-specific targeting allows for integrated regulation through multiple signaling pathways.

• Differential effects on binding interactions: The magnitude of effect varies significantly between sites:

  • T142 phosphorylation reduces binding to the C-domain of cTnC by ~14-fold

  • S149 phosphorylation reduces binding to the N-domain of cTnC by ~10-fold

  • S23/24 phosphorylation has minimal direct effect on binding to cTnC

• Functional outcomes: While all phosphorylation events affect cardiac function, they do so through different mechanisms:

  • S23/24 phosphorylation decreases calcium sensitivity and increases relaxation rate

  • T142 phosphorylation impairs the interaction with the C-domain of cTnC

  • S149 phosphorylation weakens binding to the regulatory N-domain of cTnC

The distinct location and effects of these phosphorylation sites allow for fine-tuned regulation of cardiac contraction and relaxation through different signaling pathways.

What specific advantage does phospho-TNNI3 (T142) offer as a research target compared to other phosphorylation sites?

Phospho-TNNI3 (T142) offers several unique advantages as a research target:

• PKC-specific readout: T142 is phosphorylated specifically by PKC, making it an excellent marker for PKC activity in cardiac tissue . This contrasts with S23/24, which can be phosphorylated by multiple kinases including PKA and PKC.

• Direct functional relevance: T142 phosphorylation has a dramatic effect on binding to troponin C (~14-fold reduction), providing a clear mechanism linking phosphorylation to altered cardiac function . This strong effect makes it easier to detect functional consequences in experimental systems.

• Disease relevance: The proximity of T142 to the cardiomyopathy-associated R145G mutation creates a unique opportunity to study how post-translational modifications interact with genetic variants to modulate disease presentation . This interaction is particularly valuable for understanding variable penetrance in familial cardiomyopathies.

• Region-specific effects: Unlike the N-terminal phosphorylation sites, T142 is located in the inhibitory region that directly regulates the contraction-relaxation cycle . This positioning makes it particularly important for understanding the core regulatory mechanisms of cardiac function.

• Therapeutic potential: The specific role of T142 phosphorylation in cardiac dysfunction makes it a potential target for therapeutic intervention in heart failure and cardiomyopathies. Targeting this site could potentially modulate cardiac function more precisely than targeting upstream kinases with broader effects.

How can phospho-TNNI3 (T142) analysis contribute to understanding heart failure mechanisms?

Analysis of phospho-TNNI3 (T142) provides valuable insights into heart failure mechanisms and potential therapeutic strategies:

• Biomarker potential: Changes in T142 phosphorylation often precede functional decline in heart failure models, potentially serving as an early molecular indicator of pathological PKC activation . Monitoring these changes could help identify patients at risk for heart failure progression.

• Mechanistic insights: The substantial reduction in troponin C binding caused by T142 phosphorylation (~14-fold) provides a direct molecular mechanism linking increased PKC activity in heart failure to reduced calcium sensitivity and contractile dysfunction . This mechanistic understanding helps explain how altered signaling leads to functional impairment.

• Interaction with genetic factors: The synergistic effect between T142 phosphorylation and the R145G mutation suggests that patients with certain genetic variants may be particularly vulnerable to PKC-mediated cardiac dysfunction . This interaction helps explain why some individuals with activated PKC signaling develop more severe heart failure than others.

• Therapeutic target validation: Understanding the specific effects of T142 phosphorylation helps evaluate whether PKC inhibition might be beneficial in certain heart failure subtypes. The magnitude of functional effects suggests that preventing T142 phosphorylation could significantly improve cardiac function in conditions with elevated PKC activity.

• Integration with other pathways: T142 phosphorylation can be studied alongside other post-translational modifications to understand how multiple signaling pathways converge to regulate cardiac function in heart failure. This systems biology approach helps identify key nodes for therapeutic intervention.

What emerging techniques are advancing the study of TNNI3 phosphorylation dynamics?

Cutting-edge techniques are revolutionizing our ability to study TNNI3 phosphorylation dynamics:

• Phosphorylation-specific biosensors: FRET-based biosensors that change conformation upon T142 phosphorylation allow real-time monitoring of phosphorylation dynamics in living cardiomyocytes. These tools enable researchers to observe rapid phosphorylation changes during contraction cycles and in response to stimuli.

• Mass spectrometry-based phosphoproteomics: Advanced mass spectrometry techniques now provide site-specific quantification of phosphorylation stoichiometry at multiple sites simultaneously. This approach reveals how different phosphorylation sites interact and identifies previously unknown modifications.

• CRISPR-Cas9 gene editing: Generation of knock-in models with phosphomimetic (T142D/E) or phospho-dead (T142A) mutations enables precise dissection of the physiological roles of T142 phosphorylation in cellular and animal models.

• Single-cell analysis: New techniques allow assessment of phosphorylation heterogeneity within cardiac tissue, revealing how subpopulations of cardiomyocytes may respond differently to stressors and contribute to pathological remodeling.

• Computational modeling: Integration of phosphorylation data into mathematical models of cardiac contraction helps predict functional consequences of altered phosphorylation patterns and identify potential compensatory mechanisms.

• Cryo-electron microscopy: Structural studies of the troponin complex with and without T142 phosphorylation provide atomic-level insights into how this modification alters protein conformation and interactions, complementing the functional data from biochemical studies.

• Optogenetic approaches: Light-activated kinases allow precise temporal control of T142 phosphorylation, enabling researchers to determine exactly when this modification affects cardiac function during the contraction-relaxation cycle.

These emerging techniques are advancing our understanding of how T142 phosphorylation regulates cardiac function and contributes to heart disease, potentially leading to new diagnostic and therapeutic approaches.

What are the key takeaways for researchers studying phospho-TNNI3 (T142)?

The current research on phospho-TNNI3 (T142) provides several critical insights for investigators:

• Molecular mechanism: T142 phosphorylation reduces binding to cardiac troponin C by approximately 14-fold, providing a clear mechanism for how this modification affects cardiac contraction . This substantial effect makes it an important regulatory site for cardiac function.

• Disease relevance: The interplay between T142 phosphorylation and cardiomyopathy-associated mutations suggests that this modification plays a role in cardiac pathophysiology . The synergistic effect with the R145G mutation (reducing binding by ~19-fold when combined) is particularly significant for understanding disease mechanisms.

• Experimental considerations: When studying T142 phosphorylation, researchers must carefully preserve phosphorylation status during sample preparation, use validated phospho-specific antibodies, and include appropriate controls to ensure reliable results .

• Comparative context: T142 phosphorylation should be studied in the context of other TNNI3 modifications, as multiple phosphorylation sites collectively regulate cardiac function through distinct mechanisms .

• Translational potential: Understanding T142 phosphorylation may lead to new therapeutic approaches targeting PKC signaling or its downstream effects in heart failure and cardiomyopathies. The strong functional effect of this modification makes it a promising target for intervention.

What future research directions will advance our understanding of TNNI3 phosphorylation in cardiac health and disease?

Several promising research directions will enhance our understanding of TNNI3 phosphorylation:

• Temporal dynamics: Investigating the precise timing of T142 phosphorylation during cardiac cycles and in response to various stressors will reveal how this modification contributes to beat-to-beat regulation versus long-term adaptive changes.

• Spatial heterogeneity: Exploring regional differences in T142 phosphorylation across the myocardium may explain chamber-specific dysfunction in cardiac diseases and identify targeted therapeutic approaches.

• Integration with other post-translational modifications: Comprehensive analysis of how T142 phosphorylation interacts with other modifications (phosphorylation at other sites, oxidation, S-nitrosylation, etc.) will provide a more complete understanding of TNNI3 regulation.

• Patient-specific responses: Investigating how genetic variants near phosphorylation sites affect the response to PKC activation may enable personalized approaches to heart failure treatment based on individual phosphorylation patterns.

• Novel therapeutic strategies: Developing compounds that selectively modulate the effects of T142 phosphorylation without affecting other PKC targets could provide more targeted therapeutic approaches with fewer side effects.

• Cross-species comparisons: Comparative studies across species with different heart rates and contractile properties may reveal evolutionarily conserved principles of phosphorylation-based regulation and species-specific adaptations.

• Early disease detection: Exploring whether altered T142 phosphorylation can serve as an early biomarker for cardiac dysfunction may enable earlier intervention before irreversible remodeling occurs.